3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
172
Esophageal Neoplasms
161
Esophageal Squamous Cell Carcinoma
116
Cholangiocarcinoma
77
Pancreatic Neoplasms
73
Biliary Tract Neoplasms
72
Adenocarcinoma Of Esophagus
52
Gallbladder Neoplasms
39
Colorectal Neoplasms
36
Neoplasm Metastasis
30
Carcinoma, Non-Small-Cell Lung
28
Carcinoma, Hepatocellular
28
Neoplasms
27
Bile Duct Neoplasms
24
Ovarian Neoplasms
19
Liver Neoplasms
17
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Colonic Neoplasms
13
Peritoneal Neoplasms
12
Gastrointestinal Neoplasms
12
Anus Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
11
Adenocarcinoma
11
Rectal Neoplasms
9
Melanoma
9
Lung Neoplasms
9
Carcinoma, Squamous Cell
9
Breast Neoplasms
9
Sarcoma
8
Hepatoblastoma
8
Interventions
camrelizumab
2
apatinib
2
Ramucirumab
2
trifluridine tipiracil drug combination
1
tipiracil
1
irinotecan sucrosofate
1
Trifluridine
1
S 1 (combination)
1
Fluorouracil
1
Docetaxel
1
Cisplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Gastric Adenocarcinoma
×
Cisplatin
×
Gastrointestinal
×
Clear all
NCT02314117
2021-08-26
RAINFALL
Eli Lilly and Company
Phase 3
Completed
645 enrolled
22 charts